Drug Search Results
More Filters [+]

Aldesleukin

Alternative Names: aldesleukin, proleukin, recombinant human interleukin-2, ril-2, ilt-101, ilt101
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Netherlands | New Zealand | Peru | Portugal | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Chiron
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aldesleukin

Countries in Clinic: France, Korea, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 2: Bipolar Disorder|COVID-19|Conjunctivitis, Allergic|Kidney Cancer|Renal Cell Carcinoma|Rhinitis, Allergic, Seasonal

Phase 1: Breast Cancer|Cervical Cancer|Gastrointestinal Cancer|Lung Cancer|Oncology Solid Tumor Unspecified|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Pro2022002198

P1

Recruiting

Lung Cancer|Gastrointestinal Cancer|Cervical Cancer|Breast Cancer|Uterine Cancer

2026-09-01

ATB-301-001

P1

Completed

Oncology Solid Tumor Unspecified

2023-08-21

27%

ATB-301-001

P1

Completed

Oncology Solid Tumor Unspecified

2023-08-21

27%

Rhinil-2

P2

Completed

Conjunctivitis, Allergic|Rhinitis, Allergic, Seasonal

2022-08-16

DEPIL-2

P2

Completed

Bipolar Disorder

2022-05-20

Recent News Events